Dapagliflozin Is A New Drug For The Treatment Of Type Two Diabetes – Part 3 of 3
On the other hand this drug appears to work without some of the kidney, liver and muscle complications of other drugs so “it would be excellent as an add-on to usual medications”. A second study, also simultaneously being presented at the ADA convention and published in The Lancet, found that adding inhaled insulin before each meal and long-acting insulin glargine before going to bed worked just as well as taking conventional therapy.
The frequenter therapy consisted of taking biaspart insulin twice a day. This is a combination of short-acting insulin and intermediate-acting insulin. The new regimen involved less weight gain, fewer episodes of disconsolate blood sugar and was more convenient, according to the study, which was funded by MannKind, the maker of Technosphere, the inhaled insulin featured in the trial.
A third study found that once-weekly injections of the drug Byetta (exenatide) worked better at controlling blood sugar levels than long-acting insulin. The rehearsal thus far has been to give Byetta twice a day. This study, funded by Amylin Pharmaceueticals and Eli Lilly, looked at a creative formulation of the drug. Patients who got the once-a-week form also lost an average of 2,6 kilograms (5,7 pounds), the study found.